These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
May 8, 2017Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
-
Apr 24, 2017
Pfenex Inc. (NYSE MKT: PFNX) announced today that its first quarter 2017 financial results will be released on Monday, May 8, 2017, after the market close. At 4:30 pm Eastern Time, Pfenex...
Apr 3, 2017Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
- Mar 31, 2017
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
- Mar 15, 2017
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
Mar 1, 2017Pfenex Inc. (NYSE MKT: PFNX) announced today that its fourth quarter and full year 2016 financial results will be released on Wednesday, March 15, 2017, after the market close. At 4:30 pm Eastern...
- Feb 10, 2017
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high-value and difficult to manufacture proteins, today...
-
Jan 24, 2017
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
- Dec 1, 2016
Pfenex Inc. (NYSE MKT: PFNX) ("Pfenex" or the "Company"), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture...
- Nov 9, 2016
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today...
